Research programme: imaging nanotherapeutics - Xerion Healthcare
Latest Information Update: 28 Oct 2019
At a glance
- Originator University of Oxford
- Developer Xerion Healthcare
- Class Imaging agents
- Mechanism of Action Image enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for research development in Unspecified(Diagnosis) in United Kingdom